American Heart Association and MedTech Innovator select 8 startups for Heart and Brain Health Accelerator to advance cardiovascular and neurological technologiesAmerican Heart Association and MedTech Innovator select 8 startups for Heart and Brain Health Accelerator to advance cardiovascular and neurological technologies

American Heart Association Selects Eight Startups for Heart and Brain Health Accelerator

2026/06/04 20:00
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

The American Heart Association has selected eight startups to join its Heart and Brain Health Accelerator, a specialty track within the 2026 MedTech Innovator Accelerator. The program aims to advance novel medical and digital health technologies aligned with the Association’s mission to improve heart and brain health, according to a press release.

The chosen companies, representing a global pool of early- and mid-stage startups, focus on areas including neuromodulation for dementia, atrial fibrillation treatment, intracranial embolization, heart failure detection, robotic navigation, cardiac imaging, point-of-care biomarker monitoring, and AI-guided catheter ablation. The cohort includes Cerevia Neurosciences, Chambertech, Envera Medical, Eupnoos, Flux Robotics, Lucentia, OMINI, and Prima Medical.

Through the accelerator, these companies will receive specialized mentorship, coaching, and capacity building from American Heart Association Ventures, tailored to their focus on cardiovascular and brain conditions. They also gain access to the broader MedTech Innovator program, which offers networking opportunities, funding, and increased visibility. The selected startups qualify to participate in the MedTech Innovator Competition Finals at the MedTech Conference in Boston from October 18-21, 2026, and are included in the inaugural MTI Index, a recognition platform for promising medtech companies.

“Novel approaches to tackling today’s most pressing challenges are what will drive us forward in addressing the age-old challenges of improving heart and brain health,” said Lisa Suennen, managing partner of American Heart Association Ventures. “Through the Heart and Brain Health Accelerator, we are connecting high-potential companies with the expertise, resources and networks needed to bring more trustworthy, rapid and impactful product and service advancements to patients and the clinicians who care for them.”

The selection was made by an advisory committee of clinical, investment, and industry experts, who evaluated applicants based on innovation, clinical impact, and potential to improve patient care. The collaboration between American Heart Association Ventures and MedTech Innovator highlights a growing trend of mission-driven venture capital programs bridging the gap between research and real-world impact.

For more information on the American Heart Association’s venture initiatives, visit heart.org/ventures. Details on the MedTech Innovator program can be found at MedTech Innovator.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is American Heart Association Selects Eight Startups for Heart and Brain Health Accelerator.

The post American Heart Association Selects Eight Startups for Heart and Brain Health Accelerator appeared first on citybuzz.

Market Opportunity
Humans.ai Logo
Humans.ai Price(HEART)
$0.0004659
$0.0004659$0.0004659
-27.96%
USD
Humans.ai (HEART) Live Price Chart

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage